Overview

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti- PD-(L)1 Antibody on the Treatment of uHCC

Status:
Not yet recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multi-center, exploratory study. The purpose of this study is to evaluate the efficacy, safety and the impact on the quality of life of Huaier Granules combined with targeted drugs and anti- PD-(L)1 antibody on the first-line treatment of unresectable hepatocellular carcinoma.

Phase:

Phase 4

Details

Lead Sponsor:

Fudan University

Collaborators:

Huazhong University of Science and Technology
LinkDoc Technology (Beijing) Co. Ltd.

Treatments:

Apatinib
Atezolizumab
Bevacizumab